Trial Profile
Safety and Preliminary Efficacy of ANS-6637 to Reduce Drug Craving and Harm in People With Opioid Use Disorder
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 29 Jan 2021
Price :
$35
*
At a glance
- Drugs ANS 6637 (Primary)
- Indications Opioid-related disorders
- Focus Adverse reactions; Proof of concept
- Acronyms SEARCH
- 25 Jan 2021 Planned End Date changed from 1 Dec 2021 to 12 Jan 2021.
- 25 Jan 2021 Planned primary completion date changed from 1 Dec 2021 to 12 Jan 2021.
- 25 Jan 2021 Planned initiation date changed from 1 Aug 2021 to 1 Jan 2021.